Cure My Disease

Don't miss your cure!

 Log in / Sign up

Precision surgery aims to clear dangerous brain bleeds

NCT ID NCT07697742

Disease control Sponsor: Dr. Michael D Hill Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study investigates whether a standardized microsurgical procedure can safely and effectively remove large spontaneous brain hemorrhages (bleeds) located near the brain's surface. The procedure uses a microscope and computer guidance to evacuate the clot, with the goal of leaving less than 15cc of blood behind. The study enrolls 27 adults with moderate to severe symptoms and aims to assess feasibility, safety, and how well the surgery clears the bleed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Microsurgical hematoma evacuation
What this could lead to
If successful, this approach could offer a safe and effective way to remove large brain hemorrhages, potentially improving recovery and reducing disability.
What could go wrong
This is a small, early-phase study (27 participants) focused on feasibility and safety, not yet proving benefit. Surgery carries risks like infection, bleeding, or neurological damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 27 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with spontanous lobar ICH who are appropriate for surgical evacuation.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Adults \> 18 years * CT evidence of acute, spontaneous lobar ICH defined as located \<1cm from the cortical surface * ICH volume is \>30cc but \<80cc as measured by (length x width x height)/2 * GCS 5-14 at presentation * NIHSS \>5 * Surgery deemed to be feasible within 16h of symptom onset Exclusion Criteria: * • Underlying secondary etiology (AVM, tumor, etc. if known or identifiable acutely) * Intraventricular extension estimated to involve \>50% of the lateral ventricle * Preoperative disability that will affect outcome as measured by modified Rankin Scale score (mRS\>1 at baseline) * Individuals presenting with GCS \<5 at presentation * Primary basal ganglia hemorrhage with lobar extension * End-stage organ failure or life expectancy \<6 months * For patients in whom the treating clinical team elects to proceed with surgical evacuation as part of clinical care, a standardized evacuation of the hematoma will be performed using neuronavigation for optimal craniotomy planning, microsurgical technique and SmartForceps System for quantifiable intraoperative data.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intracerebral hemorrhage lobar are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

intracerebral hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intracerebral hemorrhage lobar

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Foothills Medical Centre

    Calgary, Alberta, T2N 2T9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.